Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 1/20 | 0.65 |
| ▸ | ESR1 | P03372 | 14/20 | 0.65 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | BRAF | P15056 | 1/20 | 0.52 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.52 |
| ▸ | NQO1 | P15559 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | MAOB | P27338 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5428058 | 0.90 | CYP19A1 (0.81) | CYP19A1ESR1ESR2NPC1NQO1 | |
| SCHEMBL5142252 | 0.89 | CYP19A1 (0.74) | CYP19A1ESR1ESR2NPC1NQO1 | |
| SCHEMBL4640144 | 0.89 | ESR1 (0.64) | CYP19A1ESR1ESR2NPC1NQO1 | |
| SCHEMBL8934606 | 0.82 | CYP19A1 (0.80) | CYP19A1ESR1ESR2NPC1NQO1 | |
| SCHEMBL13713067 | 0.82 | ESR1 (0.72) | CYP19A1ESR1ESR2NQO1 | |
| SCHEMBL25079562 | 0.82 | ESR1 (0.70) | CYP19A1ESR1ESR2NPC1MEN1 | |
| SCHEMBL4640663 | 0.80 | ESR1 (0.59) | CYP19A1ESR1ESR2NPC1NQO1 | |
| SCHEMBL4639596 | 0.79 | CYP19A1 (0.62) | CYP19A1ESR1ESR2NPC1NQO1 | |
| SCHEMBL13183972 | 0.79 | ESR1 (1.00) | ESR1 | |
| SCHEMBL6818924 | 0.78 | ESR1 (0.51) | CYP19A1ESR1NQO1CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1450812-A4 | USE OF BENZOPYRANONES FOR TREATING OR PREVENTING A PRIMARY BRAIN CANCER OR A BRAIN METASTASIS | SIGNAL PHARM INC (US) | 2007-03-28 | — | — | EP | disclosed |
| US-7148252-B2 | Use of benzopyranones for treating or preventing a primary brain cancer or a brain metastasis | SIGNAL PHARMACEUTICALS, LLC (US) | 2006-12-12 | — | — | US | disclosed |
| EP-1246814-B1 | COMPOUNDS AND METHODS FOR MODULATION OF ESTROGEN RECEPTORS | SIGNAL PHARM INC (US) | 2005-02-16 | — | — | EP | disclosed |
| EP-1450812-A2 | USE OF BENZOPYRANONES FOR TREATING OR PREVENTING A PRIMARY BRAIN CANCER OR A BRAIN METASTASIS | Signal Pharmaceuticals, Inc. (US) | 2004-09-01 | — | — | EP | disclosed |
| EP-1140889-B1 | COMPOUNDS AND METHODS FOR MODULATION OF ESTROGEN RECEPTORS | SIGNAL PHARM INC (US) | 2003-08-27 | — | — | EP | disclosed |
| US-20030149025-A1 | Use of benzopyranones for treating or preventing a primary brain cancer or a brain metastasis | SIGNAL PHARMACEUTICALS, INC. | 2003-08-07 | — | — | US | disclosed |
| WO-2003028652-A2 | USE OF BENZOPYRANONES FOR TREATING OR PREVENTING A PRIMARY BRAIN CANCER OR A BRAIN METASTASIS | SIGNAL PHARMACEUTICALS, INC. (US) | 2003-04-10 | — | — | WO | disclosed |
| US-6372739-B1 | COUMARONE DERIVATIVES FOR DRUGS | SIGNAL PHARMACEUTICALS, INC. | 2002-04-16 | — | — | US | disclosed |
| US-6331562-B1 | SELECTIVELY MODULATE ESTROGEN RECEPTOR-BETA ACTIVITY; INHIBIT CYTOKINES SUCH AS INTERLEUKIN-6 | SIGNAL PHARMACEUTICALS, INC. | 2001-12-18 | — | — | US | disclosed |
| EP-1140889-A2 | COMPOUNDS AND METHODS FOR MODULATION OF ESTROGEN RECEPTORS | SIGNAL PHARMACEUTICALS, INC. (US) | 2001-10-10 | — | — | EP | disclosed |
| US-6291456-B1 | Compounds and methods for modulation of estrogen receptors | SIGNAL PHARMACEUTICALS, INC. | 2001-09-18 | — | — | US | disclosed |
| WO-2000039120-A2 | COMPOUNDS AND METHODS FOR MODULATION OF ESTROGEN RECEPTORS | SIGNAL PHARMACEUTICALS, INC. (US) | 2000-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030149025-A1 | Use of benzopyranones for treating or preventing a primary brain cancer or a brain metastasis | RB1, FOXK1, SKP1 | CYP19A1 879/4885ESR1 2470/4885ESR2 1390/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.